Format

Send to

Choose Destination
Trends Pharmacol Sci. 2019 Feb;40(2):128-141. doi: 10.1016/j.tips.2018.12.004. Epub 2019 Jan 3.

Targeting Cancer Cell Dormancy.

Author information

1
Faculty of Medicine and Health, Charles Perkins Centre, The University of Sydney, NSW 2006, Australia.
2
Faculty of Medicine and Health, Charles Perkins Centre, The University of Sydney, NSW 2006, Australia. Electronic address: lenka.munoz@sydney.edu.au.

Abstract

Cancer cell dormancy is a process whereby cells enter reversible cell cycle arrest, termed quiescence. Quiescence is essential for cancer cells to acquire additional mutations, to survive in a new environment and initiate metastasis, to become resistant to cancer therapy, and to evade immune destruction. Thus, dormant cancer cells are considered to be responsible for cancer progression. As we start to understand the mechanisms that enable quiescence, we can begin to develop pharmacological strategies to target dormant cancer cells. Herein, we summarize the major molecular mechanisms underlying the dormancy of disseminated tumor cells and drug-tolerant persister cells. We then analyze the current pharmacological strategies aimed (i) to keep cancer cells in the harmless dormant state, (ii) to reactivate dormant cells to increase their susceptibility to anti-proliferative drugs, and (iii) to eradicate dormant cancer cells.

KEYWORDS:

cancer dormancy; disseminated tumor cells; drug-tolerant persister cells; epigenetic inhibitors

PMID:
30612715
DOI:
10.1016/j.tips.2018.12.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center